Mammoth Biosciences

Mammoth Biosciences

Mammoth Biosciences is an American company based in San Francisco founded on June 1, 2017. Mammoth Biosciences uses CRISPR technology to develop bio-sensing technologies for diagnostics in industries such as healthcare, agriculture, manufacturing, and forensics.

All edits

Edits on 10 Feb, 2021
Henry Ogolla
Henry Ogolla edited on 10 Feb, 2021
Edits made to:
Timeline (+1 events) (+179 characters)
Timeline

January 28, 2021

Mammoth Biosciences, Inc. announced a co-marketing agreement with Agilent Technologies to support the anticipated launch of a complete CRISPR-based SARS-CoV-2 diagnostic solution.
Edits on 18 Nov, 2020
Aleksander Holm
Aleksander Holm edited on 18 Nov, 2020
Edits made to:
Infobox (+2 properties)
Infobox
Accelerator
Plug and Play
Accelerator Batch
Plug and Play Health Batch 6
Edits on 7 Oct, 2020
Golden AI"Location lookup using: 279 East Grand Avenue, Suite 400, South San Francisco, CA, 94080, United States"
Golden AI edited on 7 Oct, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Location
South San Francisco, California
Erin Scherfner
Erin Scherfner edited on 7 Oct, 2020
Edits made to:
Infobox (+4/--1 properties)
Infobox
Email address
careers@mammothdiagnostics.com
Full address
279 East Grand Avenue, Suite 400, South San Francisco, CA, 94080, United States
Number of Employees (ranges)
20–49
Phone number
+1-650-294-8583
Jude Gomila
Jude Gomila edited on 6 Oct, 2020
Edits made to:
Description (+6/-6 characters)
Article (+37/-38 characters)
Topic thumbnail

Mammoth Biosciences

Mammoth Biosciences is an American company based in San Francisco founded on June 1, 2017. Mammoth Biosciences uses CRISPRCRISPR technology to develop bio-sensing technologies for diagnostics in industries such as healthcare, agriculture, manufacturing, and forensics.

Article

Mammoth Biosciences is an American company based in San Francisco founded on June 1, 2017. Mammoth Biosciences uses CRISPR technology to develop bio-sensing technologies for diagnostics in industries such as healthcare, agriculture, manufacturing, and forensics. Their CRISPR platform utilizes two CRISPR proteins: Cas12 and Cas13. The technology being used by Mammoth Bioscience theoretically allows for the detection of any biomarker and/or disease that contains either RNARNA and/or DNA.

...

Mammoth Biosciences has received a disclosed amount of $23m in23min venture capital funding from MayfieldMayfield, NFX, 8VC8VC, AME CloudAME Cloud, WireframeWireframe, Kairos, and Boom Capital.

Edits on 6 Oct, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 6 Oct, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding round date
January 30, 2020
Edits on 25 Sep, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 25 Sep, 2020
Edits made to:
Infobox (+1/-1 properties)
Infobox
Total funding amount (USD)
23,000,000
Total funding amount (USD)
68,000,000
Golden AI
Golden AI edited on 25 Sep, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Funding rounds
Mammoth Biosciences Series B round, January 2020
Edits on 19 Aug, 2020
Lax Mariappan
Lax Mariappan edited on 19 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Founded date
2017
Edits on 18 Aug, 2020
Erin Scherfner"Research engine edit"
Erin Scherfner edited on 18 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 14 Aug, 2020
Jason D. Rowley"Research engine edit"
Jason D. Rowley edited on 14 Aug, 2020
Edits made to:
Infobox (--1 properties)
Infobox
Company status
Active
Edits on 12 Aug, 2020
Neelam Jhaveri"Approved suggestion #861877"
Neelam Jhaveri edited on 12 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
CEO
Trevor Martin (entrepreneur)
Edits on 17 Jul, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 17 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
23,000,000
Edits on 3 Jun, 2020
Meredith Hanel
Meredith Hanel edited on 3 Jun, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Industry
CRISPR
Edits on 11 May, 2020
Meredith Hanel
Meredith Hanel edited on 11 May, 2020
Edits made to:
Article (+276 characters)
Categories (+2 topics)
Article

Mammoth Biosciences is partnering with UC San Francisco to develop a diagnostic test to identify people infected with coronavirus, SARS-CoV-2 (previously called 2019-nCoV). The new coronavirus strain, identified December 31, 2019 is responsible for an outbreak of disease called COVID-19 that began in Wuhan, China in December, 2019 and was declared a global emergency by the World Health Organization (WHO). For current testing samples are shipped to the Centers for Disease Control and Prevention where the test can take six or more hours to complete. The test being developed by Mammoth Biosciences is expected to take one or two hours and be completed at the doctor’s office. The test would involve a nasal swab being placed in a tube with the CRISPR-Cas system and using a color-changing strip of paper to check for a positive or negative test result. Their test, uses CRISPR-Cas12a-based lateral flow assay and RT-LAMP technology and gives results in less than 40 minutes was validated in patient respiratory swab RNA extracts and results were published in April, 2020.

Categories
Edits on 12 Feb, 2020
Golden AI
Golden AI edited on 12 Feb, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Investors
Plum Alley
Edits on 11 Feb, 2020
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 11 Feb, 2020
Edits made to:
Article (+5/-5 characters)
Article

Mammoth Biosciences is partnering with UC San Francisco to develop a diagnostic test to identify people infected with coronavirus, 2019-nCoV. The new coronavirus strain, identified December 31, 2019 is responsible for an outbreak that began in WuhanWuhan, China in December, 2019 and was declared a global emergency by the World Health Organization (WHO). For current testing samples are shipped to the Centers for Disease Control and Prevention where the test can take six or more hours to complete. The test being developed by Mammoth Biosciences is expected to take one or two hours and be completed at the doctor’s office. The test would involve a nasal swab being placed in a tube with the CRISPR-Cas system and using a color-changing strip of paper to check for a positive or negative test result.

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 11 Feb, 2020
Edits made to:
Article (+5/-5 characters)
Article

Mammoth Biosciences is partnering with UC San Francisco to develop a diagnostic test to identify people infected with coronavirus, 2019-nCoV. The new coronavirus strain, identified December 31, 2019 is responsible for an outbreak that began in Wuhan, ChinaChina in December, 2019 and was declared a global emergency by the World Health Organization (WHO). For current testing samples are shipped to the Centers for Disease Control and Prevention where the test can take six or more hours to complete. The test being developed by Mammoth Biosciences is expected to take one or two hours and be completed at the doctor’s office. The test would involve a nasal swab being placed in a tube with the CRISPR-Cas system and using a color-changing strip of paper to check for a positive or negative test result.

Meredith Hanel
Meredith Hanel edited on 11 Feb, 2020
Edits made to:
Article (+821 characters)
Article

Coronavirus diagnostic

Mammoth Biosciences is partnering with UC San Francisco to develop a diagnostic test to identify people infected with coronavirus, 2019-nCoV. The new coronavirus strain, identified December 31, 2019 is responsible for an outbreak that began in Wuhan, China in December, 2019 and was declared a global emergency by the World Health Organization (WHO). For current testing samples are shipped to the Centers for Disease Control and Prevention where the test can take six or more hours to complete. The test being developed by Mammoth Biosciences is expected to take one or two hours and be completed at the doctor’s office. The test would involve a nasal swab being placed in a tube with the CRISPR-Cas system and using a color-changing strip of paper to check for a positive or negative test result.

...

Mammoth Biosciences has received a disclosed amount of $23m in venture capital funding from Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos, and Boom Capital.

Edits on 31 Jan, 2020
Golden AI
Golden AI edited on 31 Jan, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Investors
aMoon Fund
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.